Attached files

file filename
EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20170426xex99_2.htm
8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC.pacb-20170426x8k.htm

Exhibit 99.1

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



Condensed Consolidated Balance Sheets

(unaudited)



















 

 

 

 

 



 

 

 

 

 



March 31,

 

December 31,

(in thousands, except per share amounts)

2017

 

2016

Assets

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

28,982 

 

$

16,765 

Investments

 

27,068 

 

 

55,213 

Accounts receivable

 

10,441 

 

 

11,421 

Inventory

 

15,348 

 

 

15,634 

Prepaid expenses and other current assets

 

6,501 

 

 

9,978 

Total current assets

 

88,340 

 

 

109,011 

Property and equipment, net

 

42,449 

 

 

14,560 

Long-term restricted cash

 

4,500 

 

 

4,500 

Other long-term assets

 

219 

 

 

9,813 

Total assets

$

135,508 

 

$

137,884 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accounts payable

$

8,221 

 

$

8,359 

Accrued expenses

 

17,246 

 

 

16,604 

Deferred service revenue, current

 

6,683 

 

 

7,130 

Other liabilities, current

 

167 

 

 

1,681 

Notes payable, current

 

3,123 

 

 

 —

Total current liabilities

 

35,440 

 

 

33,774 

Deferred service revenue, non-current

 

1,484 

 

 

1,297 

Deferred rent, non-current

 

14,148 

 

 

19 

Other liabilities, non-current

 

1,741 

 

 

1,664 

Notes payable, non-current

 

13,302 

 

 

16,106 

Financing derivative

 

208 

 

 

356 

Total liabilities

 

66,323 

 

 

53,216 



 

 

 

 

 

Commitments and contingencies

 

 

 

 

 



 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred Stock, $0.001 par value:

 

 

 

 

 

Authorized 50,000 shares; No shares issued or outstanding

 

 —

 

 

 —

Common Stock, $0.001 par value:

 

 

 

 

 

Authorized 1,000,000 shares; Issued and outstanding 93,540 and 92,677 shares at March 31, 2017 and December 31, 2016, respectively

 

94 

 

 

93 

Additional paid-in-capital

 

880,505 

 

 

872,114 

Accumulated other comprehensive income (loss)

 

(3)

 

 

Accumulated deficit

 

(811,411)

 

 

(787,544)

Total stockholders’ equity

 

69,185 

 

 

84,668 

Total liabilities and stockholders’ equity

$

135,508 

 

$

137,884 






 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)





















 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three-Month Periods Ended March 31,

 

 

(in thousands, except per share amounts)

 

2017

 

2016

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

21,294 

 

$

12,379 

 

 

 

 

 

 

Service and other revenue

 

 

3,621 

 

 

3,152 

 

 

 

 

 

 

Contractual revenue

 

 

 —

 

 

3,596 

 

 

 

 

 

 

Total revenue

 

 

24,915 

 

 

19,127 

 

 

 

 

 

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

11,362 

 

 

6,880 

 

 

 

 

 

 

Cost of service and other revenue

 

 

4,616 

 

 

2,743 

 

 

 

 

 

 

Total cost of revenue

 

 

15,978 

 

 

9,623 

 

 

 

 

 

 

Gross profit

 

 

8,937 

 

 

9,504 

 

 

 

 

 

 

Operating expense:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

16,971 

 

 

16,361 

 

 

 

 

 

 

Sales, general and administrative

 

 

15,265 

 

 

11,708 

 

 

 

 

 

 

Total operating expense

 

 

32,236 

 

 

28,069 

 

 

 

 

 

 

Operating loss

 

 

(23,299)

 

 

(18,565)

 

 

 

 

 

 

Interest expense

 

 

(838)

 

 

(779)

 

 

 

 

 

 

Other income (expense), net

 

 

270 

 

 

(8)

 

 

 

 

 

 

Net loss

 

 

(23,867)

 

 

(19,352)

 

 

 

 

 

 

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on investments

 

 

(8)

 

 

48 

 

 

 

 

 

 

Comprehensive loss

 

$

(23,875)

 

$

(19,304)

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

 

$

(0.26)

 

$

(0.23)

 

 

 

 

 

 

Shares used in computing basic and diluted net loss per share

 

 

92,970 

 

 

83,604 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 










 

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.



Condensed Consolidated Statements of Cash Flows

(unaudited)











 

 

 

 

 



 

 

 

 

 



Three-Month Periods Ended March 31,

(in thousands)

2017

 

2016

Cash flows from operating activities

 

 

 

 

 

Net loss

$

(23,867)

 

$

(19,352)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

Depreciation

 

2,850 

 

 

848 

Amortization of debt discount and financing costs

 

319 

 

 

268 

Stock-based compensation

 

4,985 

 

 

4,581 

Other items

 

(145)

 

 

74 

Changes in assets and liabilities

 

 

 

 

 

Accounts receivable

 

980 

 

 

(2,865)

Inventory

 

366 

 

 

(2,119)

Prepaid expenses and other assets

 

3,377 

 

 

4,709 

Accounts payable

 

(5,929)

 

 

(39)

Accrued expenses

 

562 

 

 

(3,350)

Deferred service revenue

 

(260)

 

 

(705)

Deferred contractual revenue

 

 —

 

 

(3,596)

Other liabilities

 

92 

 

 

1,279 

Net cash used in operating activities

 

(16,670)

 

 

(20,267)

Cash flows from investing activities

 

 

 

 

 

Purchase of property and equipment

 

(2,668)

 

 

(457)

Disposal of property and equipment

 

 —

 

 

111 

Purchase of investments

 

(10,419)

 

 

(43,383)

Sales of investments

 

3,662 

 

 

4,949 

Maturities of investments

 

34,905 

 

 

15,539 

Net cash provided by (used in) investing activities

 

25,480 

 

 

(23,241)

Cash flows from financing activities

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

3,407 

 

 

3,423 

Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs

 

 —

 

 

26,536 

Net cash provided by financing activities

 

3,407 

 

 

29,959 

Net decrease in cash and cash equivalents

 

12,217 

 

 

(13,549)

Cash and cash equivalents at beginning of period

 

16,765 

 

 

33,629 

Cash and cash equivalents at end of period

$

28,982 

 

$

20,080 



 

 

 

 

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

Changes in unpaid property and equipment

$

5,791 

 

$

24 

Changes in deposits for property and equipment paid in prior period

$

9,694 

 

$

 —

Property and equipment paid by landlord

$

12,600 

 

 

 —